Genetic prediction of heart failure incidence, prognosis and beta-blocker response

Area of Science:

• Cardiology
• Pharmacogenomics
• Genetics

Background:

• Heart failure (HF) is a prevalent condition characterized by left ventricular dysfunction, leading to significant mortality, morbidity, and healthcare expenses.
• Current HF management relies on beta-blockers, diuretics, and ACE inhibitors/angiotensin receptor blockers, which improve survival and reduce illness.
• Individual responses to HF therapies vary, suggesting a potential role for genetic factors in treatment efficacy.

Purpose of the Study:

• To review the existing literature on the influence of candidate genes in the development and prognosis of HF.
• To examine the pharmacogenomics of beta-blocker treatment in patients with HF.
• To assess the current evidence for using genetic information to guide HF therapy.

Main Methods:

• Comprehensive literature review of studies investigating genetic factors in HF.
• Analysis of research on the pharmacogenomics of beta-blockers in HF patients.
• Evaluation of the clinical utility of genetic testing for HF treatment.

Main Results:

• The reviewed literature explores the role of candidate genes in HF development and prognosis.
• Pharmacogenomic studies of beta-blockers in HF patients indicate genetic influences on treatment response.
• Current findings do not substantiate the use of genetic tests for guiding HF therapy.

Conclusions:

• While genetics likely modifies HF progression and treatment response, current evidence is insufficient to support genetic testing in clinical practice.
• Further large-scale, well-designed genome-wide studies are necessary to establish the role of genetic tailoring in systolic HF management.
• Personalized HF therapy based on genetic profiles requires more robust scientific validation.